Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.81 |
| ▸ | TSHR | P16473 | 9/20 | 0.81 |
| ▸ | RAB9A | P51151 | 6/20 | 0.81 |
| ▸ | NPC1 | O15118 | 4/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.81 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.69 |
| ▸ | POLB | P06746 | 3/20 | 0.69 |
| ▸ | MITF | O75030 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | ATM | Q13315 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 4/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.65 |
| ▸ | PKM | P14618 | 2/20 | 0.65 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 3/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3903043 | 1.00 | ALDH1A1 (0.81) | ALDH1A1TSHRRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL3904525 | 0.90 | ALDH1A1 (1.00) | ALDH1A1TSHRRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL3905153 | 0.89 | TSHR (0.64) | ALDH1A1TSHRRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL3906023 | 0.87 | TSHR (0.88) | ALDH1A1TSHRRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL3904873 | 0.84 | TSHR (0.67) | ALDH1A1TSHRRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL13832270 | 0.82 | NPSR1 (0.68) | ALDH1A1TSHRRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL4442256 | 0.81 | ALDH1A1 (0.78) | ALDH1A1TSHRRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL28483626 | 0.80 | TSHR (0.64) | ALDH1A1TSHRRAB9ANPC1MAPT | |
| SCHEMBL3908314 | 0.80 | TSHR (0.68) | ALDH1A1TSHRRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL3913035 | 0.80 | OPRK1 (0.80) | RAB9ANPC1MEN1KMT2AOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7563905-B2 | Triazole derivatives and method of using the same to treat HIV infections | WYETH (US) | 2009-07-21 | — | — | US | claimed |
| WO-2005090320-A2 | TRIAZOLE DERIVATIVES AND METHOD OF USING THE SAME TO TREAT HIV INFECTIONS | WYETH (US) | 2005-09-29 | — | — | WO | claimed |
| US-20050209287-A1 | Triazole derivatives and method of using the same to treat HIV infections | WYETH | 2005-09-22 | — | — | US | claimed |
| US-7563905-B2 | Triazole derivatives and method of using the same to treat HIV infections | WYETH (US) | 2009-07-21 | — | — | US | disclosed |
| WO-2005090320-A2 | TRIAZOLE DERIVATIVES AND METHOD OF USING THE SAME TO TREAT HIV INFECTIONS | WYETH (US) | 2005-09-29 | — | — | WO | disclosed |
| US-20050209287-A1 | Triazole derivatives and method of using the same to treat HIV infections | WYETH | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209287-A1 | Triazole derivatives and method of using the same to treat HIV infections | CYP3A43, XDH, AKR1C3 | ALDH1A1 430/4885TSHR 2780/4885RAB9A 4291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.